<DOC>
	<DOCNO>NCT02461745</DOCNO>
	<brief_summary>This Phase IV , open-label , multi-center study evaluate real world sustain virological response rate , subject adherence , subject report outcomes treatment non-cirrhotic genotype 1 chronic hepatitis C subject age 18 year old , VIEKIRA PAK ( ombitasvir , paritaprevir/r , dasubuvir ) , without ribavirin .</brief_summary>
	<brief_title>Real World Study : Genotype 1 Chronic HCV Treatment Evaluation Real World SVR PROs</brief_title>
	<detailed_description>This Phase IV , open-label , multi-center study evaluate real world sustain virological response rate , subject adherence , subject report outcomes treatment non-cirrhotic genotype 1 chronic hepatitis C subject age 18 year old , AbbVie 3 direct-acting antiviral ( 3-DAA ) regimen VIEKIRA PAK ( ombitasvir , paritaprevir/r , dasubuvir ) , without ribavirin . Subjects may treatment-na√Øve treatment experience pegylated-interferon base regimen exclude regimen direct-acting antiviral agent . The study conduct multiple Kaiser Permanente Southern California Medical Centers . The primary objective open label study evaluate rate sustain virological response rate 12 week completion treatment ( SVR12 ) VIEKIRA PAK , without ribavirin large real world setting .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Key Inclusion Criteria Male female least 18 year age time screen . Subject , female must use estrogencontaining hormonal contraception include oral , injectable , implantable , patch ring variety study drug treatment Subject , male , surgically sterile sexually active female partner childbearing potential must agree practice 2 effective contraceptive method study duration Subject must least one follow indicator chronic hepatitis C virus infection prior study enrollment : Positive antiHCV antibody HCV RNA &gt; 10,000 IU/mL least 6 month screen , positive HCV RNA time screening , HCV RNA &gt; 10,000 IU/mL screen liver biopsy consistent chronic HCV infection Subject screen laboratory result indicate HCV genotype 1infection Key Exclusion Criteria Subject , female pregnant breastfeeding , male , female partner currently pregnant Subject positive test result hepatitis B surface antigen confirm positive antiHIV antibody test Subject receive study contraindicate medication prior study drug administration Use know strong inducer cytochrome P450 3A ( CYP3A ) strong inducer cytochrome P450 2C8 ( CYP2C8 ) strong inhibitor CYP2C8 within 2 week respective medication/supplement prior initial dose study drug . Clinically significant abnormality comorbidities , HCV infection opinion investigator make subject unsuitable study drug regimen Current enrollment another interventional clinical study prior current use investigational commercially available antiHCV agent interferon ribavirin include previous exposure ABT450 ( paritaprevir ) , ABT267 ( ombitasvir ) ABT333 ( dasabuvir ) receipt investigational product within 6 week prior study drug administration Prior treatment chronic HCV infection direct act antiviral agent ( ) : telaprevir , boceprevir , sofosbuvir , simeprevir , direct act antiviral History solid organ transplant Evidence cirrhosis History liver decompensation : ascites note physical exam , image test ; variceal bleeding ; hepatic encephalopathy Confirmed presence hepatocellular carcinoma indicate computed tomography , magnetic resonance , image technique within 3 month prior screen HCV genotype perform screen indicates infection genotype genotype 1 Recent history drug alcohol abuse could , opinion investigator , affect adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>VIEKIRA PAK</keyword>
</DOC>